DOCSLIB.ORG

Private-Public Innovation Project

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Private-Public Innovation Project GRUNDFOS BIOBOOSTER PRIVATE-PUBLIC INNOVATION PROJECT WASTEWATER TREATMENT AT HERLEV HOSPITAL, DENMARK BACKGROUND AND PROJECT OBJECTIVES HOSPITAL WASTEWATER Herlev Hospital, located in the However, (BAT) the best available Project deliverables also include: are needed to improve the removal hazardous substances and patho- CONTAINS A COMPLEX Capital Region of Denmark, faces techniques (here specifically tech- - demonstrating that air emissions of pollutants. The test programme gens. Therefore risk assessments MIXTURE OF HAZARDOUS these wastewater challenges as nology that is both technically and can be treated for pathogens and includes the evaluation of robust- are crucial instruments to evaluate PHARMACEUTICALS, the Danish government wants to economically feasible to treat the odour. ness, energy consumption and total whether the treatment technolo- HARMFUL PATHOGENS ensure that hospital wastewater hospital wastewater) has not yet - demonstrating that the by-prod- economic performance under long- gies can remove all the important AND ANTIBIOTIC is handled according to the Envi- been defined and therefore the re- ucts can be disposed of in an en- term operating conditions. risks whilst at the same time not RESISTENT BACTERIA. ronmental Protection Act’s regu- quirements for any discharge per- vironmentally sound manner. create any unintended risks. DHI lations concerning the use of the mit cannot be specified at present. - Developing a control method to will carry out environmental and THE TEST PROGRAMME THESE CANNOT BE RE- Best Available Techniques (BAT). detect when GAC filters are satu- health risk assessments in relation MOVED BY CONVENTIONAL INCLUDES THE EVALUATION Their objectives are to seek a treat- The purpose of this project is to ad- rated in order to optimise replace- OF ROBUSTNESS, ENERGY to all emissions from the WWTP MEANS OF WASTEWATER ment solution for Herlev Hospi- dress the above objectives and has ment intervals. CONSUMPTION AND TOTAL which are comprised of water efflu- TREATMENT. HOWEVER, tal’s wastewater which will allow been organised as a private-public ECONOMIC PERFORMANCE ents, sludge and air emissions. The THEY POSE A THREAT TO the hospital to obtain a license to consortium. It will demonstrate Long term performance testing of UNDER LONG-TERM risk assessments include analysis PUBLIC HEALTH, THE operate either via a permit for dis- and document the treatment ca- technologies OPERATING CONDITIONS. for pharmaceuticals, disinfectants, ENVIRONMENT AND TO charge to public sewer works or via pabilities and economic conse- The full-scale plant will be perfor- detergents, pathogens – including PEOPLE WHOSE DAILY a permit for direct discharge to a quences of a full-scale wastewater mance tested through an intensive multi-resistant bacteria – as well as WORK BRINGS THEM IN local recipient (Kags Stream). This treatment plant (WWTP) treating monitoring and test programme. Environmental and health risk as- bio-tests to measure any genotoxic CLOSE CONTACT WITH will then allow the Capital Region the wastewater at the point of Tests of each part of the technol- sessments and endocrine effects on organisms THE WASTEWATER. of Denmark and Herlev Hospital to source as opposed to, for example, ogy will be used to evaluate exactly Hospital wastewater is charac- living in water. implement their solution in other a centralised solution. where in the process adjustments terised by a complex mixture of hospitals in the region. 2 3 Gain for the environment and economic gain for the hospital TIME SCHEDULE The treatment technologies used to remove phar- maceuticals and pathogens from the hospital’s 2012 Pre-project, collection of international experience, lab-scale tests wastewater result in high quality water which should be viewed as a resource which can be uti- Planning and establishment of the full scale pilot treatment plant 2013 lised. The ultimate aim of this project is to dis- Test period and reporting of interim results charge the treated water directly into the nearby 2014 stream (Kags Stream), which needs water through Final report due the summer period. Achieving this goal will also 2015 bring the hospital a very attractive payback time on their investment. This is due to significant sav- ings on their effluent discharges to public sewer and treatment works. At the same time, the improved effluent water quality opens up for the possibility to reuse the water as technical water (cooling water/boiler water) inside the hospital and/or for use as recrea- tional water as part of the architectural design of the hospital area. Knowledge gained so far Performed pilot/lab tests on wastewater from Her- lev Hospital and Rigshospitalet in Denmark as well as other projects in Europe focusing on the elimi- nation of pharmaceuticals have shown good treat- ment results using either ozone or activated car- bon. Test results have also indicated though that both ozone and activated carbon might be needed to fully eliminate the ecotoxicity of the treated ef- fluent, even though pharmaceuticals are below the limits of detection. Previous tests raise some uncertainty as to which technology or sequence of ozone and activated carbon will be optimal from a cost/performance point of view. Full flow treatment Previous studies in the Capital Region of Denmark have proven that it is very difficult to target spe- cific pharmaceutical-rich wastewater streams. Consumption of environmentally critical pharma- ceuticals is spread across hospital departments, patients move around to toilets located in differ- ent premises of the hospital, and departments are relocated over time. At Herlev Hospital all waste- water will therefore be treated in the WWTP to en- sure that no hazardous pharmaceuticals, harmful pathogens or antibiotic resistant bacteria will end up in the environment. 4 5 OpEN UP FOR DENMARK’S MOST ADVANCED WWTP This full-scale pilot wastewater treatment plant Featuring: (WWTP) will have a capacity that matches a small - Wastewater treated for pharamceuticals, harmful town with 2500 inhabitants. pathogens and antibiotic resistant bacteria, A glass front allows by-passers to get an inside look - Air emissions treated for pathogens and odour of what will become Denmark’s most advanced WWTP. 6 7 Combined buffer- and bioprocess tanks Post-treatment Air treatment ABOUT THE FULL SCALE PILOT In order to find the ideal way of eliminating pharma- All process related air emissions are treated using pho- ceuticals, the post-treatment has been divided into two toionisation, UV light and a catalyst before release in or- WASTEWATER TREATMENT PLANT parallel operating lines: Post-treatment line 1 and Post- der to eliminate pathogens and odours from the air; it treatment line 2. is therefore safe to install a wastewater treatment plant close to a hospital. Post-treatment line 1 Line 1 consists of Granular Activated Carbon, followed Disposal of debris and bio-sludge The pilot WWTP will have a capacity that matches a The MBR part by Ozone and/or H 0 . All debris from inlet screens and excess sludge from small town with 2500 inhabitants. The plant design is based around an MBR system 2 2 This skid is equipped with an option to add H O prior to the biological process are sent to incineration in order When completed it will be the most advanced WWTP (Membrane Biological Reactor) which consists of Ozone reaction tank 2 2 ozone injection which ensures the full transformation to completely eliminate any threats from these sources. in Denmark equipped with membrane bioreactors, biological process tanks followed by ultra-filtration of ozone into hydroxyl radicals. The latter oxidizes the As the bio-sludge contains pharmaceuticals both in the activated carbon and ozone technologies and will pro- membrane for the retention of biomass. The resultant pharmaceutical much faster and more effectively than microbes and in the water phase, the bio-sludge cannot vide a very high water quality similar to that of drink- particle and bacteria free water provides optimal con- molecular ozone. be dewatered after leaving the site as this will release ing water levels. ditions for the next post-treatment step and allows for pharmaceuticals into the environment again. To keep the adjustment of the biological treatment capacity to GAC tanks Finally the skid uses UV light to eliminate any residual the cost of transport and incineration to a minimum Plant definition match the hospital’s future requirements in the same ozone before discharge and as an extra safety barrier and improve handling, the bio-sludge is dewatered and Herlev Hospital will be expanded in terms of both ac- process tanks. against pathogens. dried on site by up to 90%, this dry matter is then stored tivities and buildings. Additional medical specialities in big bags which are transported directly to the incin- and an expansion of the on-site sterilisation centre The process tanks work as combined buffer and pro- Air blowers for bioprocess Post-treatment line 2 eration plant. will also be assembled at the hospital. The number of cess tanks. All biological processes take place inside Line 2 consists of Ozone followed by Granular Activated beds will increase from 595 beds to 825 beds and the the process tanks. The process tanks can be operated Carbon. This skid also has UV light as an extra safety number of people working at the hospital will increase with or without full removal of Nitrogen (using in- barrier against pathogens. from about 4000 people to about 6000 people. termittent aeration) and Phosphorous (through
Load more

Recommended publications
  • Sygehusspecifikke Nøgletal
    Bilag 2: Sygehusspecifikke nøgletal Sygefravær blandt ansatte på sygehusene Publikationen kan hentes på hjemmesiden for Økonomi- og Indenrigsministeriets Benchmarkingenhed: www.oimb.dk Henvendelse om publikationenkan ske til kontaktpersonen på analysen, som fremgår af hjemmesiden. 1 Indhold 1 Sygefravær blandt alle ansatte ........................................................................................................... 3 2 Sygefravær blandt sygeplejersker ..................................................................................................... 5 3 Sygefravær blandt Social- og sundhedspersonale .......................................................................... 7 4 Sygefravær blandt læger ..................................................................................................................... 9 2 1 Sygefravær blandt alle ansatte Tabel 1.1 Sygefravær målt i fraværsdagsværk pr. fuldtidsansat blandt alle ansatte Forventet Sygehus 2015 2016 2017 Benchmarkingindikator 2017* Amager og Hvidovre Hospital 10.9 10.8 10.8 9.9 109 Bispebjerg og Frederiksberg Hospi- 11.2 10.3 9.9 9.8 101 tal Bornholms Hospital 9.5 9.0 10.4 11.1 93 Herlev og Gentofte Hospital 10.5 9.9 10.2 9.9 103 Holbæk Sygehus 10.4 11.1 10.8 9.9 109 Hospitalsenhed Midt 9.9 10.0 9.9 10.3 96 Hospitalsenhed Vest 9.2 10.1 10.1 10.0 101 Nordsjællands Hospital 12.0 12.0 11.6 10.7 108 Nykøbing F. Sygehus 11.5 13.3 11.7 10.5 111 Næstved Slagelse og Ringsted 11.5 11.0 10.0 10.1 98 Sygehuse Odense Universitetshospital 10.0 10.0 9.8 10.1 97 Regionshospital Nordjylland 8.6 9.3 8.9 10.5 84 Regionshospitalet Horsens 9.5 9.4 10.5 10.1 104 Regionshospitalet Randers 9.6 10.0 10.2 10.4 97 Rigshospitalet 10.1 10.0 10.1 9.7 104 Sjællands Universitetshospital 10.1 10.4 10.1 9.7 104 Sydvestjysk Sygehus 8.5 8.5 8.3 10.1 81 Sygehus Lillebælt 9.9 9.5 9.8 9.9 99 Sygehus Sønderjylland 10.3 10.5 10.2 10.3 99 Aalborg Universitetshospital 8.9 9.2 9.0 9.8 91 Aarhus Universitetshospital 10.0 10.1 10.0 9.7 102 Landsgennemsnit 10.1 10.1 10.0 - - Anm.: *Angiver antal fraværsdagsværk pr.
    [Show full text]
  • VVM Letbane På Ring 3
    Letbane på Ring 3 VVM-redegørelse Maj 2015 cv cv Udgivet af: Transportministeriet Frederiksholms Kanal 27F 1220 København K Udarbejdet af: Transportministeriet ISBN, trykt: 978-87-93292-09-3 ISBN, elektronisk: 978-87-93292-08-6 Kort vedr. trafik og støj: Copyright Geodatastyrelsen. cv cv Indhold Indhold ........................................................................................................... 1 1. Ikke-teknisk resumé ............................................................................... 1 1.1. Projektet ..................................................................................... 1 1.2. Trafik .......................................................................................... 3 1.3. Støj .............................................................................................. 6 1.4. Vibrationer .................................................................................. 7 1.5. Landskab og arkitektur ............................................................... 8 1.6. Kulturarv ..................................................................................... 8 1.7. Jord ............................................................................................. 9 1.8. Grundvand .................................................................................. 9 1.9. Afvanding .................................................................................. 10 1.10. Materialer, råstoffer og affald ................................................... 10 1.11. Luft ...........................................................................................
    [Show full text]
  • Aalborg Universitet the Danish Myelodysplastic Syndromes
    Aalborg Universitet The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records Lauritsen, Tine Bichel; Nørgaard, Jan Maxwell; Grønbæk, Kirsten; Vallentin, Anders Pommer; Ahmad, Syed Azhar; Hannig, Louise Hur; Severinsen, Marianne Tang; Adelborg, Kasper; Østgård, Lene Sofie Granfeldt Published in: Clinical Epidemiology DOI (link to publication from Publisher): 10.2147/CLEP.S306857 Creative Commons License CC BY-NC 4.0 Publication date: 2021 Document Version Publisher's PDF, also known as Version of record Link to publication from Aalborg University Citation for published version (APA): Lauritsen, T. B., Nørgaard, J. M., Grønbæk, K., Vallentin, A. P., Ahmad, S. A., Hannig, L. H., Severinsen, M. T., Adelborg, K., & Østgård, L. S. G. (2021). The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. Clinical Epidemiology, 13, 439-451. https://doi.org/10.2147/CLEP.S306857 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research. ? You may not further distribute the material or use it for any profit-making activity or commercial gain ? You may freely distribute the URL identifying the publication in the public portal ? Clinical Epidemiology Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records Tine Bichel Lauritsen 1 Background: The Danish Myelodysplastic Syndromes Database (DMDSD) comprises Jan Maxwell Nørgaard 1 nearly all patients diagnosed with myelodysplastic syndromes (MDS) in Denmark since Kirsten Grønbæk2–4 2010.
    [Show full text]
  • 2. Gazeller Fordelt På
    Gazeller i Københavns Amt 2006 Omsætning*/ Vækst % Navn By bruttoresultat Ansatte (1.000 kr) 940,5 1a Farma A/S** Albertslund 64343* 3 798,1 Liqtech A/S - Gazellevinder Gentofte 31783* 33 750,5 Updata Danmark A/S Glostrup 33177 19 671,7 Plaston A/S Herlev 28814* 2 670,0 Intervare A/S Rødovre 17787 47 609,7 MMJ Brolægning A/S Virum 5323 7 606,2 Cdrator A/S Ballerup 23864* 29 528,9 Scandiapack ApS Hellerup 9785 5 484,5 Spa Supply A/S Hvidovre 9317 14 481,8 Drive In Bottle Shop ApS Kastrup 12282 10 470,9 Griffin Ejendomme A/S Glostrup 237788* 9 465,6 Rovsing A/S Charlottenlund 32897 60 460,0 Segmenta A/S Brøndby 10002 16 455,6 Prof-Il Service A/S Ballerup 35454 110 446,4 H.J. Byg A/S Hedehusene 3535 7 432,0 Jens Nielsen Total- Entreprise A/S Charlottenlund 4884 13 423,3 Lyprodan A/S Hellerup 8896 - 418,5 VeriSign Denmark ApS Søborg 13776* 12 415,7 A2m Statsautoriseret Revisionsaktieselskab Brøndby 3182 5 409,4 Beton-Apoteket ApS Taastrup 5807* - 400,5 Cbrain A/S Hellerup 4324 6 375,4 Koki Europe A/S Ishøj 42402* 17 372,0 Spiritus Distillers A/S Vedbæk 26524 5 367,4 Unique Trading Danmark A/S Brøndby 8437 14 359,2 Falsing El ApS Gentofte 4009 10 357,4 Pan-Form ApS Skovlunde 6852 19 344,5 Bidsted & Co. A/S Hellerup 25427 14 339,8 Lector ApS Charlottenlund 10266 20 339,2 Copenhagen Airports International A/S Kastrup 60552* 25 338,2 Mogens Elmer A/S Kastrup 91192* 27 325,0 Kvisgårds Maskinfabrik A/S Rødovre 20413 29 306,4 HK Byg ApS Charlottenlund 12281* 9 305,6 DIBS A/S Kongens Lyngby 13097 14 300,2 Skagen Designs A/S Albertslund 21142 22 293,8 Jørgen Jacobsen Automobiler ApS Brøndby 7227 - 293,7 Investas ApS Taastrup 4142 14 289,0 Danamedic ApS Klampenborg 4400 1 287,3 Connect Partner A/S Herlev 48363 100 280,8 Sugro Danmark A/S Brøndby 64213* 5 276,5 Compare Support A/S Skovlunde 34860 77 274,1 GN Netcom A/S Ballerup 1978052* 320 271,0 Kjeld B.
    [Show full text]
  • Letbanen I Herlev – En Ny Transportmulighed I 2020/21
    Transportministeriet Linjeføring i Herlev v/Herlev Hospital Letbanen i Herlev – en ny transportmulighed i 2020/21 Letbanen standser ved Herlev Hospital v/Herlev Hovedgade Herlev v/Lyskær Mulige letbanelinjeføringer i Herlev Transportministeriet Letbane fra Lyngby til Ishøj 2020/21 Her kører letbanen i Herlev Letbanen er midtlagt på hele strækningen gennem Herlev Kom- Gilleleje / Tisvildeleje Helsingør mune. Første station i kommunen er ved Herlev Hospital station, Hillerød Hillerød Syd Nærum Allerød Helsingør umiddelbart nord for indkørslen til hospitalet. Birkerød v/Lundtofte Frederiksværk Holte v/DTU v/Lyngby centrum v/Akademivej Virum v/Gammelmosevej v/Lyngbygårdsvej Klampenborg Sorgenfri Farum Lyngby Ordrup Letbanens linjeføring i 2020/21 Stationer i Herlev Kommune Værløse Hareskov Charlottenlund (stationsnavnene er ikke fastlagt): Skovbrynet Buddinge Bagsværd Jægersborg Efter hospitalet passeres kryds ved Gentofte Stengården v/Buddingecentret Hjortespringsvej og Herlev Bygade. • ved Herlev Hospital Bernstorffsvej Kildebakke Hellerup Vangede v/Gladsaxevej Næste station er placeret umiddelbart • ved Herlev Hovedgade Dyssegård v/Gladsaxe Emdrup Trafikplads Svanemøllen nord for Herlev Hovedgade tæt ved • Herlev FrederikssundØlstykke Egedal v/Dynamovej Orientkaj Ryparken Fuglebakken Herlev Bymidte. • ved Lyskær Stenløse Bispebjerg Poul Henningsens Veksø Nørrebro Plads v/Herlev Hospital Vibenshus Kildedal Runddel Nordhavn Måløv M4 Skjolds Plads v/Herlev Trianglen Hovedgade Ved Herlev S-togsstation placeres Ballerup Østerport Herlev Grøndal
    [Show full text]
  • No Effect of Dietary Fish Oil on Renal Hemodynamics, Tubular Function, and Renal Functional Reserve in Long-Term Renal Transplant Recipients1
    No Effect of Dietary Fish Oil on Renal Hemodynamics, Tubular Function, and Renal Functional Reserve in Long-Term Renal Transplant Recipients1 Jesper Meichior Hansen,2 Hans L#{248}kkegaard, Carl-Erik H#{248}y,Niels Fogh-Andersen, Niels Vidlendal Olsen, and Svend Sfrandgaard supplementation with fish oil in these patients did not J.M. Hansen, N.y. Olsen, Department of Clinical improve renal function. Physiology, Herlev Hospital, University of Copenhagen, Key Words: Amino acids, cyclosporin A, GFR, lithium clear- Herlev, Denmark once, renal circulation H. L#{248}kkegaard, S. Strandgaard, Department of Nephrology, Herlev HospItal, University of Copenha- T he use of cyclosporin A (CsA) in clinical immuno- gen, Herlev, Denmark suppression is associated with nephrotoxlcity, characterized by a dose-dependent, initially reversible N. Fogh-Andersen, Department of Clinical Chemistry, decline in the GFR and RBF (1 ,2). The renal hemody- Herlev Hospital, University of Copenhagen, Herlev, namic changes are most likely due to a direct CsA- Denmark induced constriction of the afferent arteriole (3). The C.-E. H#{248}y,Department of Biochemistry and Nutrition, precise mechanism of this vasoconstriction is still Technical UniversIty of Denmark, Lyngby, Denmark unclear, but some evidence does suggest a CsA-in- (J. Am. Soc. Nephroi. 1995; 5:1434-1440) duced alteration in the synthesis of the eicosanoids (4-6). In addition to the renal functional changes, prolonged treatment with CsA may cause structural ABSTRACT lesions in the kidney with arteriolopathy and intersti- Dietary supplementation with fish oil rich In n-3 poly- tial fibrosis (7). unsaturated fatty acids has been suggested to pro- Previous studies in CsA-treated animals (4,8) and humans (9-1 1) have demonstrated that a dietary tect the kIdney agaInst cyclosporin A (CsA) toxicity.
    [Show full text]
  • Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing in Vitro Fertilization Treatment
    Daytime variation in serum progesterone during the mid-luteal phase in women undergoing in vitro fertilization treatment Thomsen, Lise Haaber; Kesmodel, Ulrik Schiøler; Andersen, Claus Yding; Humaidan, Peter Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2018.00092 Publication date: 2018 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Thomsen, L. H., Kesmodel, U. S., Andersen, C. Y., & Humaidan, P. (2018). Daytime variation in serum progesterone during the mid-luteal phase in women undergoing in vitro fertilization treatment. Frontiers in Endocrinology, 9(MAR), [92]. https://doi.org/10.3389/fendo.2018.00092 Download date: 02. okt.. 2021 ORIGINAL RESEARCH published: 19 March 2018 doi: 10.3389/fendo.2018.00092 Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment Lise Haaber Thomsen1,2*, Ulrik Schiøler Kesmodel 3,4, Claus Yding Andersen 5 and Peter Humaidan1,2 1 The Fertility Clinic, Skive Regional Hospital, Skive, Denmark, 2 Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 3 The Fertility Clinic, Herlev Hospital, Herlev, Denmark, 4 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 5 Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, University of Copenhagen, Copenhagen, Denmark Objective: To investigate whether mid-luteal serum progesterone (P4) exhibits significant fluctuations during a 12-h daytime period in women undergoing in vitro fertilization (IVF) and to explore whether the extent of these fluctuations could impact the interpretation of luteal progesterone levels in a clinical setting.
    [Show full text]
  • Characteristics and Outcomes After Confirmed Infection in Pregnancy
    medRxiv preprint doi: https://doi.org/10.1101/2021.06.08.21258480; this version posted June 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . COVID-19 in pregnancy SARS-CoV-2 infection in pregnancy in Denmark – characteristics and outcomes after confirmed infection in pregnancy: a nationwide, prospective, population-based cohort study Anna JM Aabakke, MD, PhD1,2, Lone Krebs, MD, DMSc2,3, Tanja G Petersen, MScPH, PhD4, Frank S Kjeldsen, MScPH4, Giulia Corn5, Karen Wøjdemann, MD, PhD6, Mette H Ibsen, MD7, Fjola Jonsdottir, MD8, Elisabeth Rønneberg, MD8, Charlotte S Andersen9, Iben Sundtoft, MD, PhD9, Tine Clausen, MD, PhD2,10, Julie Milbak10, Lars Burmester, MD11, Birgitte Lindved, MD12, Annette Thorsen-Meyer, MD3, Mohammed R Khalil, MD, PhD13, Birgitte Henriksen13, Lisbeth Jønsson, MD14, Lise LT Andersen, MD15, Kamilla K Karlsen, MD, PhD15, Monica L Pedersen16, Åse Klemmensen, MD, PhD17, Marianne Vestgaard, MD, PhD17, Dorthe Thisted, MD18, Manrinder K Tatla, MD18, Line S Andersen, MD19, Anne-Line Brülle20, Arense Gulbech, MD20, Charlotte B Andersson, MD21,22, Richard Farlie, MD, MHM23, Lea Hansen24, Lone Hvidman, MD, PHD24, Anne N Sørensen, MD, PhD25, Sidsel L Rathcke, MD25, Katrine H Rubin, PhD, MHS4,26, Lone K Petersen, MD, DMSc15, 26, Jan S Jørgensen, MD, PhD15,26, Lonny Stokholm, MScPH4,26, Mette Bliddal, PhD4,26 1. Department of Obstetrics and Gynecology, Copenhagen University Hospital - Holbæk, Holbæk, Denmark 2. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark 3.
    [Show full text]
  • Specialevejledning for Gynækologi Og Obstetrik, 29
    29-09-2014 Specialevejledning for Sagsnr. 4-1012-14/7 gynækologi og obstetrik Reference KSA T 7222 7400 Specialevejledningen indeholder en kort beskrivelse af hovedopgaverne i specialet E [email protected] samt den faglige og organisatoriske tilrettelæggelse af specialet. Dernæst følger Sundhedsstyrelsens anbefalinger til hovedfunktionsniveauet. De godkendte regi- ons- og højt specialiserede funktioner, herunder krav og placeringer, fremgår ba- gerst i specialevejledningen. Specialebeskrivelse Gynækologi omfatter forebyggelse, diagnostik og behandling af sygdomme og symptomer i de kvindelige kønsorganer, behandling af kvinder med kønshormonre- laterede sygdomme, diagnostik og behandling af infertilitet, svangerskabsforebyg- gelse, problemer i den tidlige graviditet og svangerskabsafbrydelse. Gynækologi omfatter endvidere diagnostik og behandling af kvinder med sygdomme, der skyl- des forandringer i bækkenbund og nedre urinveje. Obstetrik omfatter sundhedsfremme, forebyggelse, diagnostik og behandling under svangerskab, fødsel og barselsperiode. Desuden varetager specialet den prænatale genetiske rådgivning og de prænatale diagnostiske prøveudtagninger i et nært sam- arbejde med de genetiske centre. Specialet varetager desuden forskning, udvikling og uddannelse inden for specia- lets områder. Hovedopgaver I gynækologi er der følgende hovedopgaver: Almen gynækologi og gynækologisk endokrinologi: Godartede sygdomme i livmoder, æggestokke, æggeleder og skeden, tidlige graviditetskomplika- tioner samt hormonelle forstyrrelser som følge af sygdom
    [Show full text]
  • Transfers of Value Re Research & Development As Defined
    SCHEDULE 2 - TEMPLATE Full Name HCPs: City of Principal Practice Country of Principal Practice Principal Practice Address Unique Country Identifier Donations and Grants to HCOs Contribution to Costs of Events Fee for Service and Consultancy (Art. 1.01) HCOs: City Where Registered (Schedule 1) (Art. 3) (Art. 3) (Art. 3.01.1.a) (Art. 3.01.1.b & 3.01.2.a) (Art. 3.01.1.c & 3.01.2.c) Related Expenses Agreed in the Fee for Total (Art. 3) Sponsorship Agreements with HCOs/ Service or Consultancy Contract, Including Registration Fees Travel & Accommodation Fees Third Parties Appointed by HCOs to Manage Travel & Accommodation Relevant to the an Event Contract INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) Md Hazem Hassan Al-hashemi Herlev Denmark Herlev Ringvej, 2730 00YXK N/A N/A 7600 11389 0 0 18989 Professor Berit Andersen Randers Denmark Skovlyvej 15, 8930 00R4T N/A N/A 0 2786.32 0 0 2786.32 Nurse Rikke Lænsø Baltzer Aarhus C Denmark Nørrebrogade 44, 8000 N/A N/A 0 5461.13 7441.48 232.05 13134.66 Overlæge Gunnar Bastrup Svendborg Denmark Baagøes Alle 31, 5700 080156-xxxx N/A N/A 0 0 5000 0 5000 Clinical Dietitian Mette Borre Aarhus Denmark Nørrebrogade 44, 8000 05KG2 N/A N/A 0 5983 4000 0 9983 MD Mustafa Bulut Køge Denmark Lykkebækvej 1, 4600 05HMY N/A N/A 2405 3780 0 0 6185 Chief Physician Annette Dam Fialla Odense Denmark J.
    [Show full text]
  • Pulje Til Videreudvikling Og Styrkelse Af Indsatser I Kommunerne Med Særligt Fokus På Ældre Medicinske Patienter Og Udsatte Grupper
    Pulje til videreudvikling og styrkelse af indsatser i kommunerne med særligt fokus på ældre medicinske patienter og udsatte grupper Oversigt over projekter, der har modtaget midler. Ansøger Projekt Bevilget beløb (kr.) Nordfyns Kommune Styrkelse af sundhedsfaglig indsats og 960.780 samarbejde på psykiatri- og handicapområdet Allerød Kommune "Mit liv med osteoporose" 286.400 Frederikshavn Kommune Osteoporoserehabilitering - på vej mod 478.355 sundhed med lyst til livet Københavns Kommune, Online understøttet rehabilitering til borgere 2.787.500 Center for Kræft & med hoved-halskræft Sundhed, København Faaborg-Midtfyn Tidlig opsporing af begyndende fysisk- 2.525.556 Kommune og/eller forværring af psykisk sygdom Mariagerfjord Kommune Opkvalificering af den sundhedsfaglige 841.626 indsats på de kommunale pædagogiske botilbudslignende botilbud Herning Kommune Fremskudt sundhedstilbud i udvalgte 939.000 boligområder Rudersdal Kommune Sundhedssamtaler på tværs 1.158.315 Stevns Kommune En styrket koordineret indsats mellem almen 1.203.742 praksis og akutfunktion i Stevns kommune Fredensborg Kommune Implementering af Sundhedsstyrelsens 492.000 anbefalinger om afklarende samtaler og udvikling af tilhørende tilbud til borgere med kroniske smerter Vordingborg Kommune Styrkelse af akutindsatsen 957.198 Norddjurs Kommune Hjælp til lokale lunger 2.240.000 Kerteminde Kommune Socialsygeplejerske i kommunale 2.141.000 akutfunktioner hos borgere med psykiatrisk lidelse og/eller misbrug Helsingør Kommune Koordinering og kvalitetssikring af 400.500 sundhedsfaglig
    [Show full text]
  • Letbanen I Rødovre – En Ny Transportmulighed I 2020/21
    Transportministeriet Linjeføring i Rødovre Letbanen i Rødovre – en ny transportmulighed i 2020/21 v/Lyskær Letbanen kører under broen ved Slotsherrensvej Kontrol- og Vedligeholdelses- center v/Islevbro Mulige letbanelinjeføringer i Rødovre Transportministeriet Letbane fra Lyngby til Ishøj 2020/21 Her kører letbanen i Rødovre Syd for ved Lyskær station (i Herlev) passerer letbanen ind Gilleleje / Tisvildeleje Helsingør i Rødovre Kommune. Hillerød Hillerød Syd Nærum Allerød Helsingør Birkerød v/Lundtofte Frederiksværk Holte v/DTU v/Lyngby centrum v/Akademivej Virum v/Gammelmosevej v/Lyngbygårdsvej Klampenborg Letbanens linjeføring i 2020/21 der skal ind og ud af Kontrol­ og Vedlige­ Sorgenfri Farum holdelsescentret, skal krydse ringvejen. Lyngby Ordrup Værløse På begge sider af ringvejen ligger koloni­ Krydsningen, der bliver signalreguleret, Hareskov Charlottenlund Skovbrynet Buddinge haveområder og letbanens linjeføring er vil være sammenbygget med hovedlin­ Bagsværd Jægersborg Gentofte Stengården midtlagt på denne strækning. Syd for jens oven for beskrevne krydsning af de v/Buddingecentret Kildebakke Bernstorffsvej Hellerup Vangede kolonihaveområderne passeres under­ nordgående vejbaner i forbindelse med v/Gladsaxevej Dyssegård v/Gladsaxe Emdrup føringer for Harrestrup Å og en parallelt skiftet fra midtlagt til østlagt linjeføring. Trafikplads Svanemøllen FrederikssundØlstykke Egedal v/Dynamovej Orientkaj løbende sti. Begge underføringer skal Tog til og fra KVC fra nord skal krydse Ryparken Fuglebakken Stenløse Bispebjerg Poul Henningsens Veksø Nørrebro Plads v/Herlev udvides mod øst. Efter at have passeret ringvejens sydgående vejbaner, mens Hospital Vibenshus Kildedal Runddel Nordhavn Måløv M4 Skjolds Plads rampestrækningen fra Slotsherrensvej, tog til og fra KVC fra syd skal krydse v/Herlev Trianglen Hovedgade Ballerup Østerport Herlev Grøndal krydser letbanen ringvejens nordgående både ringvejens nordgående og syd­ Nørrebros Malmparken M3 Runddel Skovlunde vejbaner og bliver østliggende.
    [Show full text]